Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Generic Office Director Uhl Returns From Medical Leave

This article was originally published in The Pink Sheet Daily

Executive Summary

Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.

You may also be interested in...



Generics Office At US FDA Could Get New Director Before Uhl Departs

Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel